Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

Among patients with high-risk or metastatic prostate cancer who were initially diagnosed with and treated for nonmetastatic tumors, germline DNA repair variants in BRCA2 do not confer a substantially worse prognosis.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-10-25
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2483
Citations
8
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
3.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

Kenneth Offit, Joseph Vijai, Mark M. Pomerantz, Michael J. Morris et al.
8 citations
Clinical Cancer Research
Prostate Cancer Treatment and Research
3.35
article

Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

Kenneth Offit, Joseph Vijai, Mark M. Pomerantz, Michael J. Morris, Michael Conry, Gwo‐Shu Mary Lee, Yelena M. Kemel, Samantha E. Vasselman, Dory Freeman, Lorelei Ann Mucci, Kathryn L. Penney, Konrad Hermann Stopsack, Philip W. Kantoff, Jacob E. Berchuck, Wassim Abida, Diana L. Mandelker, David B. Solit
article en
8 citations

Abstract

Among patients with high-risk or metastatic prostate cancer who were initially diagnosed with and treated for nonmetastatic tumors, germline DNA repair variants in BRCA2 do not confer a substantially worse prognosis.

Clinical Cancer ResearchVol. 31(1)
Brigham and Women's Hospital (US), American Cancer Society (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Emory University (US), Cornell University (US), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Convergent Science (United States) (US)
Prostate Cancer Foundation, Dana-Farber/Harvard Cancer Center, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 7%
Prostate Cancer Treatment and Research
3.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.